Medipharm Labs Corp T.LABS

LABS partners with McMaster University Big Industry News:

[Oceanis]

MediPharm Labs Enters Research Agreement with McMaster University to Develop Drugs Containing Cannabis Candidates

GlobeNewswireJun 21, 2021 7:00 AM EDT

• MediPharm Labs’ Cannabis Drug Licence and expertise qualifies and positions the Company to supply clinical trial material, assist in investigation protocol and provide regulatory support for multiple trials 
   
• Three initial proposed clinical trials will evaluate the effectiveness of proprietary THC and CBD drug candidates for multiple indications including Pain, Insomnia associated with Major Depression, and Uremic Pruritus. 

BARRIE, Ontario, June 21, 2021 (GLOBE NEWSWIRE) -- MediPharm Labs Corp . (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality development and manufacturing of cannabis API and derivative products, is pleased to announce it has entered into a research partnership Master Agreement (the “Agreement”) with McMaster University. The Agreement is a key step that enables MediPharm Labs to work with McMaster University’s large and diversified roster of clinicians leading the way in cannabis research and drug development.

Under the terms of the Agreement, MediPharm Labs will enter into a separate Statement of Work with each clinician group. MediPharm Labs will use its Cannabis Drug Licence to provide access to clinical trial material that meets pharmaceutical quality standards and Good Manufacturing Practice (GMP), as well as investigative protocol and regulatory approval support.

MediPharm Labs and McMaster University researchers have proposed three distinct clinical trials, each led by separate clinician groups looking to develop novel cannabis-based drugs to treat different indications including pain, insomnia associated with major depression, and uremic pruritus.

MediPharm Labs will assist in the development of the study drugs that will be evaluated, and each will name a Principal Investigator physician. MediPharm Labs’ expertise in formulation and delivery methods will be critical to the execution of these trials. Before each study begins, all necessary approvals from relevant regulatory authorities, including Health Canada, will be obtained.

“As a pharmaceutical company specialized in cannabis, MediPharm Labs is excited to participate in the development of drugs containing cannabis. This will further our initiative to fulfill the global need for pharmaceutically approved drugs containing cannabis. We are honoured to partner with McMaster University, a global leader in medical cannabis research.” said Keith Strachan, President and Interim CEO, MediPharm Labs.

The Company looks forward to further announcements regarding specific projects under the Agreement as the projects receive initial Health Canada support.

About MediPharm Labs

 

[Righttothetop]

Lovely....and a supreme waste of time and resources.  The time for this kind of longer term planning has passed....it's game time now and execution is required....not a 10yr novel drug odyssey. The only thing LABS is doing with this is gifting an acquirer entry into the pharma market.  Hardly useful and important to existing shareholders.

[lscfa]

Fire the interim CEO too.

[inventors]

Labs turning into a costly tesearch centre....R&D not very profitable...?

[Oceanis]

you won't be saying that when they start producing all the drugs that cannabis will (inevitabily) be approved for.

[Righttothetop]

You understand how long a drug R&D cycle typically goes for right?  They are in the change room at the moment and aren't even on the track to get into the starting blocks....so while I would agree that pharma solutions would be wickedly lucrative; it ain't happening for a good looooooong time.  Laying the groundwork is fine enough, but if it's costing money or manpower

[beaniw]

A different opinion posted on LinkedIn a few hours ago: "Another notable credibility boost for MediPharm Labs (LABS #TSX $0.47 / MEDIF #OTCQX / MLZ #FSE) as they partner with McMaster University on #cannabis #painmanagement & #insomnia. This further elevates Medipharm near the forefront as a Cannabis #pharmaceutical company

[Righttothetop]

If an exclusive European partnership with a pharma doing north of $2billion Euros annually didn't do anything for our credibility....not sure what a scratch and sniff NR with Mac is going to do; especially in the short term. It ain't a bad news story....but it's ain't what we need either and they need to keep their eye on the going concern ball more than developing drugs that won&

[Oceanis]

I should, I'm in the buisness.

[Righttothetop]

Then you should know how costly this kind of endeavour is, how rare it is to progess a drug candidate through approval and how many companies outright fail because of the weight of the first two items. LABS needs to be profitable before it burns money on drug trials...plain and simple.

[lscfa]

Prospectus says co. will spend $400,000 for R&D, which is likely for the clinical trial materials. NR does not say how or if LABS shares in any successful outcomes.     

[lscfa]

Weak NR.    At least with Mount Sinai co. jpintly owns IP.      MediPharm Labs and Timeless Herbal will jointly own any intellectual property developed during the clinical trials (“Developed IP”), excluding the Formulation, and MediPharm Labs will be the exclusive manufacturer for products resulting from this study. https://stockhouse.com/news/press-releases/2019

[jayc1]

Are these two different partnerships? i mean Macmaster trails will be different?